0 -
Sigma Aldrich 236005 The COX-1 Inhibitor, FR122047, also referenced under, controls the biological activity of COX-1. This small molecule/inhibitor is primarily used for Cell Signaling applications 5 mg
Brand
Stock Code
LB.SA.236005-5MG
Kısa Bilgi
Synonym(s): COX-1 Inhibitor, FR122047, FR 122047, 1-[(4,5-Bis(4-methoxyphenyl-2-thiazoyl)carbonyl]-4-methylpiperazine, Hydrochloride, 4,5-Bis(4-methoxyphenyl-2-[(1-methylpiperazin-4-yl)carbonyl]thiazole, Hydrochloride Empirical Formula (Hill Notation): C23H25N3O3S · xHCl CAS Number: 130717-51-0 Molecular Weight: 423.53 (free base basis) UNSPSC Code: 51111800 NACRES: NA.77
Market Price
CAS Number: 130717-51-0
| Sigma Aldrich 236005 The COX-1 Inhibitor 5 mg |
| Synonym(s): COX-1 Inhibitor, FR122047, FR 122047, 1-[(4,5-Bis(4-methoxyphenyl-2-thiazoyl)carbonyl]-4-methylpiperazine, Hydrochloride, 4,5-Bis(4-methoxyphenyl-2-[(1-methylpiperazin-4-yl)carbonyl]thiazole, Hydrochloride Empirical Formula (Hill Notation): C23H25N3O3S · xHCl CAS Number: 130717-51-0 Molecular Weight: 423.53 (free base basis) UNSPSC Code: 51111800 NACRES: NA.77 |
|
PROPERTIES
Quality Level 100
Assay ≥98% (HPLC) form solid manufacturer/tradename Calbiochem® storage condition OK to freeze desiccated (hygroscopic) protect from light color pale yellow solubility 1 M HCl: 2 mg/mL water: 4 mg/mL DMSO: 5 mg/mL shipped in ambient storage temp. 2-8°C InChI 1S/C23H25N3O3S.ClH/c1-25-12-14-26(15-13-25)23(27)22-24-20(16-4-8-18(28-2)9-5-16)21(30-22)17-6-10-19(29-3)11-7-17;/h4-11H,12-15H2,1-3H3;1H InChI key YWMAVHIKOAOSFM-UHFFFAOYSA-N DESCRIPTION General description A cell-permeable trisubstituted thiazole compound that acts as a potent and selective inhibitor of COX-1 (IC50 = 28 nM and 65 µM for human recombinant COX-1 and COX-2, respectively). Displays ~2,300 fold greater selectivity towards inhibition of COX-1 over COX-2. Reported to be orally active and display analgesic, anti-platelet and anti-inflammatory properties. A potent, cell-permeable, and selective inhibitor of COX-1 (IC50 = 28 nM; human recombinant COX-1). Does not significantly inhibit COX-2 (IC50 = 65 µM, human recombinant COX-2). Reported to be orally active and displays analgesic properties in chemical nociceptive animal models. Also reported to exhibit anti-inflammatory effects and suppress prostaglandin E2 and thromboxane 2 levels in collagen-induced arthritis in rats. Shown to be 100 times more potent than aspirin in inhibiting arachidonic acid- and collagen-induced human and guinea pig platelet aggregation. Biochem/physiol Actions Cell permeable: yes Primary Target COX-1, COX-2 Product does not compete with ATP. Reversible: no Target IC50: 28 nM and 65 µM for human recombinant COX-1 and COX-2 Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Ochi, T., and Goto, T. 2002. Br. J. Pharmacol.135, 782. Ochi, T., et al. 2000. Eur. J. Pharmacol.391, 49. Tanaka, A., et al. 1994. J. Med. Chem.37, 1189. Dohi, M., et al. 1993. Eur. J. Pharmacol.243, 179. Legal Information CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany |